Global Pentavalent Vaccine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pentavalent Vaccine Market Insights, Forecast to 2034
A pentavalent vaccine is a five-in-one vaccine that protects against diphtheria, tetanus, and whooping cough, hepatitis B, and Haemophilus influenza type b with just one dosage. One of the most well-known and successful techniques of preventing paediatric diseases is vaccination. The Government of India has achieved tremendous progress in preventing and controlling vaccine-preventable diseases since implementing the Universal Immunization Programme (UIP) (VPDs). The introduction of a pentavalent vaccination will help to minimise the number of cases of pneumonia and meningitis caused by the germs Haemophilus influenzae type b (Hib).
Global Pentavalent Vaccine market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pentavalent Vaccine industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Pentavalent Vaccine key manufacturers include Serum Institute of India, Panacea Drugs Pvt. Ltd, Shantha Biotechnics, Biological E. Ltd., Novartis AG, Crucell and Bio Farma, etc. Serum Institute of India, Panacea Drugs Pvt. Ltd, Shantha Biotechnics are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Pentavalent Vaccine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Pentavalent Vaccine market and estimated to attract more attentions from industry insiders and investors.
Pentavalent Vaccine can be divided into Lyophilized and Liquid, etc. Lyophilized is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Pentavalent Vaccine is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and E-commerce,, etc. Retail Pharmacy provides greatest supports to the Pentavalent Vaccine industry development. In 2022, global % sales of Pentavalent Vaccine went into Retail Pharmacy filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Pentavalent Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pentavalent Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Serum Institute of India
Panacea Drugs Pvt. Ltd
Shantha Biotechnics
Biological E. Ltd.
Novartis AG
Crucell
Bio Farma
Segment by Type
Lyophilized
Liquid
Retail Pharmacy
Hospital Pharmacy
E-commerce
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pentavalent Vaccine plant distribution, commercial date of Pentavalent Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pentavalent Vaccine introduction, etc. Pentavalent Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Pentavalent Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Pentavalent Vaccine market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pentavalent Vaccine industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Pentavalent Vaccine key manufacturers include Serum Institute of India, Panacea Drugs Pvt. Ltd, Shantha Biotechnics, Biological E. Ltd., Novartis AG, Crucell and Bio Farma, etc. Serum Institute of India, Panacea Drugs Pvt. Ltd, Shantha Biotechnics are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Pentavalent Vaccine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Pentavalent Vaccine market and estimated to attract more attentions from industry insiders and investors.
Pentavalent Vaccine can be divided into Lyophilized and Liquid, etc. Lyophilized is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Pentavalent Vaccine is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and E-commerce,, etc. Retail Pharmacy provides greatest supports to the Pentavalent Vaccine industry development. In 2022, global % sales of Pentavalent Vaccine went into Retail Pharmacy filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Pentavalent Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pentavalent Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Serum Institute of India
Panacea Drugs Pvt. Ltd
Shantha Biotechnics
Biological E. Ltd.
Novartis AG
Crucell
Bio Farma
Segment by Type
Lyophilized
Liquid
Segment by Application
Retail Pharmacy
Hospital Pharmacy
E-commerce
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pentavalent Vaccine plant distribution, commercial date of Pentavalent Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pentavalent Vaccine introduction, etc. Pentavalent Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Pentavalent Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports